U.S. markets open in 2 hours 26 minutes
  • S&P Futures

    4,154.25
    -14.75 (-0.35%)
     
  • Dow Futures

    34,185.00
    -133.00 (-0.39%)
     
  • Nasdaq Futures

    13,335.25
    -51.75 (-0.39%)
     
  • Russell 2000 Futures

    2,205.10
    -17.60 (-0.79%)
     
  • Crude Oil

    65.30
    -0.07 (-0.11%)
     
  • Gold

    1,849.40
    +11.30 (+0.61%)
     
  • Silver

    27.73
    +0.36 (+1.33%)
     
  • EUR/USD

    1.2168
    +0.0022 (+0.18%)
     
  • 10-Yr Bond

    1.6350
    0.0000 (0.00%)
     
  • Vix

    20.63
    -2.50 (-10.81%)
     
  • GBP/USD

    1.4101
    -0.0001 (-0.00%)
     
  • USD/JPY

    109.1400
    -0.2070 (-0.19%)
     
  • BTC-USD

    44,500.94
    -5,021.82 (-10.14%)
     
  • CMC Crypto 200

    1,237.87
    -120.69 (-8.88%)
     
  • FTSE 100

    6,997.00
    -46.61 (-0.66%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

Recap: Arbutus Biopharma Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 6.0% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 50.00% year over year to ($0.23), which missed the estimate of ($0.22).

Revenue of $2,386,000 higher by 47.47% year over year, which beat the estimate of $1,960,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Mar 04, 2021

View more earnings on ABUS

Time: 08:45 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/kv9k7xnj

Recent Stock Performance

52-week high: $9.02

52-week low: $0.88

Price action over last quarter: Up 22.58%

Company Profile

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.